免疫疗法 – 2080. Fel d 1 衍生肽抗原脱敏导致在 4 剂后 1 年对猫过敏症状的持续治疗效果
World Allergy Organization Journal
(
IF
4.3
)
Pub Date : 2013-01-01
, DOI:
10.1186/1939-4551-6-s1-p162
Roderick Peter Hafner
,
Peter Couroux
,
Annemarie Salapatek
,
Pascal Hickey
,
Paul Laidler
,
Mark Larché
,
Deepen Patel
背景 此前，我们从主要猫过敏原 Fel d1 中鉴定了一系列 T 细胞表位，并表明这些表位在对猫过敏受试者给药时是安全且耐受良好的。在目前的研究中，我们评估了两种具有相同累积剂量的治疗方案在开始给药一年后的治疗效果（耐受性）的持续性。方法 受试者连续 4 天在环境暴露室 (EEC) 中接受基线挑战，包括 3 小时过敏原暴露 (Fel d1 50.19±3.70 ng/m3)。受试者每 30 分钟对四种鼻部症状和四种眼部症状进行评分，评分范围为 0-3。202 名受试者被随机分配到安慰剂组、8x3nmol 猫肽抗原脱敏 (Cat-PAD) 组，间隔 2 周（周）或 4x6nmol Cat-PAD 组，间隔 4 周。受试者连续 4 天重新参加 EEC，每次 3 小时，治疗开始后18-22wk。治疗开始后 50-54wk 受试者被邀请参加不进一步给药的盲法后续研究。招募了 89 名受试者，并在 EEC 中继续连续 4 天（3 小时）。
"点击查看英文标题和摘要"
Immunotherapy – 2080. Fel d 1 derived peptide antigen desensitization results in a persistent treatment effect on symptoms of cat allergy 1 year after 4 doses
Background Previously, we identified a series of T-cell epitopes from the major cat allergen Fel d1 and showed these were safe and well-tolerated when administered to cat allergic subjects. In the current study, we evaluated persistence of the treatment effect (tolerance) one year after start of dosing for two treatment regimens with the same cumulative dose. Methods Subjects underwent Baseline Challenge in an Environmental Exposure Chamber (EEC) on 4 consecutive days, consisting of 3-hour allergen exposures (Fel d1 50.19±3.70 ng/m3). Subjects scored four nasal and four ocular symptoms every 30 minutes each on a scale of 0-3. 202 subjects were randomised to placebo, 8x3nmol Cat Peptide Antigen Desensitisation (Cat-PAD) 2weeks(wk) apart or 4x6nmol Cat-PAD 4wk apart. Subjects re-attended the EEC for 4 consecutive days, of 3-hours, 18-22wk after the start of treatment. 50-54wk after commencement of treatment subjects were invited to participate in a blinded follow-on study without further dosing. 89 subjects were enrolled and had a further 4 consecutive days, of 3-hours in the EEC.
